Litigation Details for Mitsubishi Tanabe Pharma Corporation v. Lupin Limited (D. Del. 2025)

Mitsubishi Tanabe Pharma Corporation v. Lupin Limited (D. Del. 2025)

Docket		Date Filed	2025-07-03
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Parties	LUPIN LIMITED
Patents	10,987,341; 11,241,416; 11,478,450; 11,826,352; 11,957,660; 12,285,409
Attorneys	Jeremy A. Tigan
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Mitsubishi Tanabe Pharma Corporation v. Lupin Limited (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-07-03				External link to document

Last updated: July 25, 2026

tsubishi Tanabe v. Lupin (1:25-cv-00828) Patent Litigation Summary and Analysis

Mitsubishi Tanabe Pharma Corporation (MTPC) and Lupin Limited are litigating an Orange Book patent challenge tied to MTPC’s US product(s), filed in the District of Delaware under case number 1:25-cv-00828. The matter is in early procedural posture; the available record excerpted here does not include the complaint, asserted patents, drug/NDAs involved, claims/constructions, or any schedule or settlement terms.

What is the Mitsubishi Tanabe Pharma v. Lupin 1:25-cv-00828 litigation about?

Answer: The case is a US patent infringement proceeding filed by MTPC against Lupin Limited in Delaware under civil action number 1:25-cv-00828.

What court and parties are involved?

• Case: 1:25-cv-00828
• Court: US District Court for Delaware (D. Del.)
• Plaintiff: Mitsubishi Tanabe Pharma Corporation
• Defendant: Lupin Limited

What type of dispute is it (ANDA/Orange Book context)?

No document-level details are present in the provided information (no NDA numbers, no Paragraph IV labels, no Orange Book listing citations, no Hatch-Waxman notice text, and no asserted patent numbers). Without those, the litigation type cannot be mapped to specific statutory hooks with accuracy.

Which patents are asserted in MTPC v. Lupin (1:25-cv-00828)?

Answer: The asserted patent list is not available in the supplied material.

What information is needed to identify asserted patents?

A complete answer requires at least one of: the complaint’s “Patents-in-suit” section, the infringement contentions, or a docket entry with patent numbers and claims. None appears in the provided excerpt.

What is the procedural status and timeline for 1:25-cv-00828?

Answer: Early-stage posture is implied by the single case identifier, but no filing dates, motion practice milestones, scheduling order dates, or trial setting is included here.

What typically drives the schedule in ANDA patent cases?

In Delaware ANDA litigations, key milestones usually include:

• complaint filing and service
• answer
• Rule 12 motions (if any)
• case schedule order (claim construction, infringement/validity expert deadlines)
• Markman/claim construction hearings
• summary judgment or dispositive Daubert motions
• pretrial and trial dates
  No such entries are contained in the information provided.

How strong is MTPC’s patent estate in this case?

Answer: Patent strength cannot be evaluated from the information provided because the patent numbers, independent claims at issue, relevant jurisdictions (US only vs. foreign counterparts), and claim themes (composition vs. method of use vs. formulation vs. manufacturing) are missing.

What would be used for an evidence-based strength view?

A litigation-grade strength analysis depends on:

• asserted claim scope (composition vs. formulation vs. method)
• prosecution history estoppel indicators
• written description and enablement posture
• obviousness-type attack surface (prior art mapping)
• validity defenses that drive potential stay outcomes
  Those inputs are not present here.

What generic entry risks exist for Lupin if MTPC’s patents are upheld?

Answer: Entry risk cannot be quantified without knowing the asserted patents’ effective dates, claim type, and whether any automatic stay is in effect based on the Orange Book listing and the FDA notice.

What would normally govern entry timing?

For Paragraph IV-style disputes, risk turns on:

• whether the litigation triggers a 30-month stay
• whether patents are later held not infringed/invalid
• whether exclusivity (SFE, 5-year) or exclusivity tied to exclusivity codes is still active
  No Orange Book/NDA-specific exclusivity indicators are provided.

Is this litigation a Paragraph IV challenge under Hatch-Waxman?

Answer: The filing is associated with Orange Book-type patent litigation, but the record provided does not confirm the statutory basis (e.g., 35 USC § 271(e)(2)) or whether the dispute stems from a Paragraph IV notice.

What would confirm Paragraph IV?

Confirmation requires at least one of:

• the complaint referencing a § 355(j)(2)(A)(iv) notice
• docket entries quoting the notice letter
• the Orange Book patent listing and NDA/ANDA pairing
  None is included in the supplied information.

What settlement or consent-judgment outcomes are possible for 1:25-cv-00828?

Answer: No settlement agreement, consent judgment, or stipulation text is provided.

What to look for in docket outcomes

In similar Delaware ANDA cases, resolution often appears as:

• stipulated dismissal without prejudice
• dismissal with prejudice after a license
• permanent injunction terms (rare if generic has not launched)
• carve-outs for non-infringing products
  No such docket content is available in the provided material.

What is the FDA regulatory posture tied to MTPC’s product in this case?

Answer: The FDA status cannot be determined from the information provided because the NDA, ANDA number, ANDA applicant (Lupin entity), drug strength/dosage form, and Orange Book listing identifiers are missing.

What FDA items typically map to the patent claims

A correct linkage requires:

• NDA and Orange Book listing(s) for MTPC’s active ingredient
• relevant FDA exclusivity codes
• ANDA submission date and amendments
• labeling at issue (approved indications and off-label method claims)
  None is present in the supplied excerpt.

How does MTPC v. Lupin compare with other MTPC generic-challenge litigations?

Answer: No comparable cases or consolidated litigation information is provided.

What comparison metrics matter

A useful comparison would cover:

• asserted patent families and frequency of infringement findings
• validity outcomes at Markman and summary judgment stages
• settlement patterns and per-product launch timing
  No comparative dataset is available in the provided information.

Key Case-Analysis Limits Based on Provided Record

• Asserted patents-in-suit: not provided.
• Claims at issue and claim themes: not provided.
• ANDA/NDA linkage, Orange Book listings, and FDA exclusivity: not provided.
• Procedural milestones, injunction posture, or stay status: not provided.
• Settlement terms or license conditions: not provided.

Key Takeaways

• MTPC v. Lupin Limited, 1:25-cv-00828, is a Delaware patent litigation identified by case number and parties.
• The provided information does not include the asserted patent numbers, the Orange Book/NDA/ANDA nexus, or any docket outcomes, so litigation merits, strength, and entry-risk cannot be evaluated from this record.
• A litigation-grade analysis requires complaint-level patent and claim identifiers and any docket milestones; those are not included in the material provided.

FAQs

1) What is the earliest event usually shown on the docket in cases like 1:25-cv-00828?
The filing of the complaint and service/answer entries typically appear first, followed by a scheduling order.

2) Does a Delaware ANDA patent case automatically include Paragraph IV issues?
Often it does, but it is not universal; it depends on the Orange Book listing and the notice type, which is not specified in the provided record.

3) What milestones determine whether Lupin faces a launch stay?
The Paragraph IV notice and the timing of suit can trigger a statutory stay, but stay status depends on the NDA and notice details not present here.

4) What claim categories are most common in Orange Book litigations?
Composition, method-of-use, and formulation/manufacturing claims are common, but the category cannot be stated without the patents-in-suit.

5) How do settlements usually show up in the docket?
They typically appear as stipulated dismissals, consent judgments, or docketed license terms, none of which is provided here.

References

1. US District Court for the District of Delaware. Case 1:25-cv-00828: Mitsubishi Tanabe Pharma Corporation v. Lupin Limited.